{"url_path":"/sec/dmra/8-k/2026-06-17/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1800315/0001193125-26-274093-index.html","accession_number":"0001193125-26-274093","cik":"0001800315","ticker":"DMRA","issuer_name":"Damora Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1800315/0001193125-26-274093-index.html","primary_entity_key":"0001800315","primary_entity_name":"Damora Therapeutics, Inc."},"word_count":438,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\n \n\nDamora Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders on June 17, 2026 (the “Annual Meeting”). The following proposals were submitted to the stockholders of the Company at the Annual Meeting, which are described in detail in the the Company’s [Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001800315/000119312526191429/dmra-20260429.htm) (the “Proxy Statement”):\n\n1.\nTo elect Michael Landsittel and Cameron Turtle, D.Phil, as Class III members of the Board of Directors (the “Board”), to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal (the “Election of Directors Proposal”);\n\n2.\nTo approve, on an advisory basis, the compensation paid to the Company’s named executive officers (the “Say-on-Pay Proposal”);\n\n3.\nTo conduct an advisory vote on the frequency of future advisory votes to approve the compensation paid to the Company’s named executive officers (the “Say-on-Frequency Proposal”); and\n\n4.\nTo ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (the “Ratification of Auditor Proposal”).\n\nThere were 60,303,212 shares of Common Stock outstanding and entitled to vote on April 22, 2026, the record date for the Annual Meeting, and 55,009,938 shares of Common Stock were represented in person or by proxy at the Annual Meeting, which number constituted a quorum.\n\n \n\nAt the Annual Meeting, each of the Company’s director nominees was elected, a frequency of one year received the plurality of votes cast on the Say-on-Frequency Proposal and the other proposals voted on were approved. The final voting results regarding each proposal are set forth below.\n\n1.\nElection of Directors Proposal.\n\n \n\nNominees\n\n \n\nFor\n\n \n\nWithheld\n\n \n\nBroker Non-Votes\n\nMichael Landsittel\n\n \n\n51,403,541\n\n \n\n29,011\n\n \n\n3,577,386\n\nCameron Turtle, D.Phil\n\n \n\n51,403,540\n\n \n\n29,012\n\n \n\n3,577,386\n\n \n\n2.\nSay-on-Pay Proposal.\n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n51,401,988\n\n \n\n3,546\n\n \n\n27,018\n\n \n\n3,577,386\n\n \n\n3.\nSay-on-Frequency Proposal.\n\n \n\n1 Year\n\n \n\n2 Years\n\n \n\n3 Years\n\n \n\nAbstain\n\n50,913,167\n\n \n\n103\n\n \n\n518,015\n\n \n\n1,267\n\n \n\nIn light of these voting results and in accordance with its prior recommendation, the Board has determined that the Company will hold future Say-on-Pay votes every year until the next required Say-on-Frequency vote.\n\n \n\n4.\nRatification of Auditor Proposal.\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n54,977,317\n\n \n\n5,640\n\n \n\n26,981\n\n \n\n-\n\n \n\n \n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDamora Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate: June 17, 2026\n\n \n\nBy:\n\n/s/ Jennifer Jarrett\n\n \n\n \n\n \n\nJennifer Jarrett\n\n \n\n \n\n \n\nPresident and Chief Executive Officer"}